Symposium 9. Evidence based or gut reaction

Similar documents
Systematic review and meta-analysis: the clinical and physiological effects of fibre-containing enteral formulae

4.5 Composition of Enteral Nutrition: Strategies for optimizing EN and minimizing risks of EN: Fibre March 2013

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

Management of Diarrhea in Critical Ill Patients CCSSA Congress Sun City 20. October 2017

Health Benefits of Prebiotic Dietary Fiber

Treat primary. symptoms. Offer general lifestyle advice. Manage IBS according to the dominant symptom. Follow up. Symptoms do not improve

MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES

Current International Regulatory Positions on Prebiotics

Injection Techniques Questionnaire (ITQ) WorldWide Results Needle Gauge

Physiology of the gut and mechanisms of prebiotic effect. Joanne Slavin, Ph.D, R.D. Department of Food Science and Nutrition University of Minnesota

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017

Patient Information Leaflet MOVICOL Paediatric Plain 6.9g sachet, powder for oral solution

Angie Jefferson Registered Dietitian & Consultant Nutritionist

function, gastrointestinal discomfort,

SUBMISSION FOR THE RECLASSIFICATION OF SODIUM PICOSULPHATE FROM PRESCRIPTION MEDICINE TO PHARMACY MEDICINE

A patient s guide to the. management of constipation following surgery

PRODUCT INFORMATION. New Reagents for Dako CoverStainer. Choose the H&E staining intensity you want.

Health Care Providers:

Allied Health: Sustainable Integrated Health Care for all Australians

Louisville '19 Attachment #69

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link System. Fully-Automated HbA 1c Testing

Providing a Universal, One-step Alternative to Liquid-Liquid Extraction in Bioanalysis

Current dietary habits in Europe far from plant based eating

IBS Practical Advice for Patients

DOES ENTERAL NUTRITION CAUSE DIARRHOEA & LOOSE STOOLS?

Authors and Disclosures

30/07/2018. Defining Fibre - Challenges & Controversies. Fibre Definitions

Opioid Induced Constipation Lisa Clince Acute Pain CNS Palmerston North Hospital

MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)

Bio-Rad Laboratories HEMOGLOBIN Testing Bio-Rad A1c. VARIANT II TURBO Link. Fully-Automated HbA 1c Testing

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON PSYLLIUM SEED (PLANTAGO AFRA ET PLANTAGO INDICA, SEMEN)

Ever wonder what s really happening on the inside?

Nutrition and Cancer: What We Know, What We Don t Know Walter C. Willett, MD, DrPH

25 September 2012 Early Years Pathfinder. misuse. Insert name of presentation on Master Slide. Presenter: Dr Sarah J Jones

Urgent Medical Device Correction

Results you can trust

MOVICOL Junior Powder for Solution (macrogol 3350)

Understanding the SACN Report on Carbohydrates & Health

Package Leaflet: Information for the Patient. FOSRENOL 750 mg oral powder. FOSRENOL 1000 mg oral powder. lanthanum

Table 6.1 Summary information for colorectal cancer in Ireland,

Gastrointestinal Involvement in Adult Mitochondrial Disease

Fibre-supplemented tube feeding in the hospitalised elderly

Health Maintained and Restored Begins With Nutrition


MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350)

Evidence and Recommendations for the Use of Prebiotics in Clinical Settings

PosterREPRINT INTRODUCTION. 2-D PAGE of Mouse Liver Samples. 2-D PAGE of E.coli Samples. Digestion / Cleanup. EXPERIMENTAL 1-D PAGE of BSA Samples

Gut microbiota: importance

MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350)

Tobacco control measures in the Dutch National Prevention Agreement and expected tobacco industry responses

Package Leaflet: Information for the user Laxido Paediatric Plain 6.9 g, powder for oral solution

My dog or cat has problems with the stomach, intestines or liver... what do I do now?

Pharmaceutical, Medical and Health-related Government and Regulatory bodies around the world.

Chemical compatibility of the Pall QPoint TM Docking Station - Tap Assembly with common surface disinfectants

Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis

Constipation in children

ABDOMINAL PAIN, CHRONIC

World Connections Committee (WCC) Report

Food, climate change and human health

2017 ICF GLOBAL CONSUMER AWARENESS STUDY

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

BioPlex 2200 Infectious Disease Panels

European Medicines Agency Evaluation of Medicines for Human Use

Fonterra Probiotics: From guts to glory

Canadian Cochrane Network & Centre. Copyright 05/12/2009 by Phil Hahn

STATS Relationships between variables: Correlation

- Network for Excellence in Health Innovation

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON PLANTAGO OVATA FORSSK., SEMINIS TEGUMENTUM

MOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l

The role of gut microbiome in IBS

COMPLETE DIGESTIVE STOOL ANALYSIS - (CDSA) Level 4

IBS. Patient INFO. A Guide to Irritable Bowel Syndrome

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Foreword. Dr Hilary Jones. debilitating digestive health conditions.

PACKAGE LEAFLET: INFORMATION FOR THE USER. PEGLAX 10g Powder for oral solution in sachet. Macrogol 4000

Prof. Renata Cífková, MD, CSc.

WORKING PARTY ON HERBAL MEDICINAL PRODUCTS FINAL PROPOSAL FOR A CORE DATA FOR ISPAGHULA HUSK

Injection Techniques Questionnaire (ITQ) WorldWide Results Insulin Usage

Importance of fibres and Multi Fibre in enteral nutrition. Clinical Evidence Overview

Fiber: What Is It and What Does It Do? By James L. Holly, MD. Your Life Your Health. The Examiner. May 5, 2005

ApplicationNOTE EXACT MASS MEASUREMENT OF ACTIVE COMPONENTS OF TRADITIONAL HERBAL MEDICINES BY ORTHOGONAL ACCELERATION TIME-OF-FLIGHT.

ABDOMINAL PAIN, CHRONIC

The first and only fully-automated, multiplexed solution for Measles, Mumps, Rubella and Varicella-zoster virus antibody testing

Sperm donation Oocyte donation. Hong Kong þ Guideline þ þ Hungary þ þ þ þ Israel þ þ þ þ Italy þ þ þ. Germany þ þ þ þ Greece þ þ þ þ

Bio-Rad Laboratories. Hemoglobin Testing. VARIANT II Hemoglobin Testing System For HbA 1c

Real Life, Real PD Survey

HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer

Efficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club

Prostate Cancer Screening: Risks and Benefits across the Ages

FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?

PACKAGE LEAFLET: INFORMATION FOR THE USER

MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa

Latest research on fibre and gut health

DIVERTICULOSIS MEDICAL AND SURGICAL MANAGEMENT. Simon Radley Consultant Surgeon March 2013

Primary Management of Irritable Bowel Syndrome

Acute GI effects of radiotherapy

Transcription:

Symposium 9 Ch i E t l F d Choosing Enteral Feeds Evidence based or gut reaction

All enteral feeds should contain fibre Ceri Green Global Medical Department Numico Clinical Nutrition Division Schiphol, The Netherlands BAPEN, 28th November 2007, Harrogate, UK

The argument is based on four platforms Recommendations Evidence base 3

Fibre is recognised as an essential part of the normal diet Australia Austria Belgium Canada C. America Columbia Denmark Finland France Germany India Ireland Italy Dietary recommendations for fibre are available in many countries, such as. Japan Mexico Netherlands Norway Puerto Rico South Africa Spain Sweden Switzerland Venezuela UK USA WHO/FAO 4

Fibre has many physiological effects which are relevant for enterally fed patients Dietary component FIBRE Physiological effect Stool bulking Fermentation to produce SCFA Microflora balance Mode of action Water holding Microbial mass Speed transit time Mucosal fuel source H 2 0/Na reabsorption Prebiotic effect Gut barrier Health Improved Metabolic benefit Control Maintenance of normal bowel function and gut health/integrity 5

Use of fibre-containing enteral formulas is growing in clinical practice (but still room for improvement ) 100 80 60 40 Fibre-free Fibre 20 0 2002 2003 2004 2005 2006 6

Systematic review and meta-analysis: the clinical and physiological effects of fibre-containing enteral formulae Elia M, Engfer MB, Green CJ, Silk DBA. Aliment Pharmacol Ther, in press Enteral nutrition as primary source of nutrition Fibre vs fibre free formula Minimum 3 days Studies included Outcomes 51 studies (43 RCTs) 38 in patients (n = 1591) Intensive care/critically ill Surgical/post-operative operative Medical Chronic care Paediatrics 13 in healthy volunteers (n = 171) Incidence diarrhoea, constipation, stool consistency, GI symptoms Transit time, stool weight, bowel frequency QUORUM Guidelines (1999) 7

FIbre significantly reduces the incidence of diarrhoea compared with fibre-freefree enteral feeds Study name Spapen et al. 2001 Guenter et al. 1991 Frankenfield & Beyer 1989 Dobb & Towler 1990 Schultz et al. 2000 Schultz et al. 2000 Schultz et al. 2000 Hart & Dobb 1988 Khalil et al. 1998 Reese et al. 1996 Reese et al. 1996 Homann et al. 1994 de Kruif et al. 1993 Richardson et al. 1987 Belknap et al. 1997 Hofman et al. 2001 Group by: /non- Ward Fiber type Odds ratio and 95% CI non- non- non- non- non- non- non- non- non- Overall Surgical Surgical Surgical Surgical Surgical Surgical Medical Pediatric Guar Soy Soy Soy Fiber mixture* Pectin Fiber mixture* + pectin Soy Soy + oat Soy (7 g/l)) Soy (14 g/l) Guar Soy Soy Psyllium Fiber mixture** 16 studies (13 RCTs) fibre n = 338 non-fibre n = 345 OR 0.68 95% CI 0.48-0.96 p= 0.03 non- OR 0 68 0.01 0.1 1 10 100 Favors fiber Favors fiber free 8

Fibre reduces laxative use in the acute and chronic settings compared wth fibre-free free feeds Type of setting Reduced use of elimination aids with fibre (no. studies) Acute 3 out of 4 Chronic 2* out of 4 * NS in one study 9

Fibre improves objective parameters of bowel function compared with fibre-freefree feeds in healthy volunteers Bowel frequency Transit time Faecal mass (times/day) (hours) (g/day) Number RCTs 9 (14) 7 (14) 7 (12) (data sets) Fibre/no fibre 154/153 175/175 129/129 (no. patients) Result fibre versus fibre free + 0.14 (SE 0.05) (p=0.005) - 9.3 (SE 2.29) (p<0.001) + 35 (p<0.001) Conclusion Favours Favours Favours fibre fibre fibre 10

Meta-regression shows modulating effect of fibre on bowel function 0.60 0.46 0.32 0.18 means Difference in 0.04-0.10-0.24-0.38 038-0.52-0.66-0.80 0.44 0.56 0.69 0.81 0.94 1.07 1.19 1.32 1.44 1.57 1.70 Bowel frequency in fiber-free free group (times/day) 11

Meta-regression shows modulating effect of fibre on bowel function 0.60 0.46 0.32 0.18 Difference in means 0.04-0.10 010-0.24-0.38-0.52-0.66-0.80 0.44 0.56 0.69 0.81 0.94 1.07 1.19 1.32 1.44 1.57 1.70 Fibre increases bowel frequency when it is low (constipation) Bowel frequency in fiber-free group (times/day) Fibre decreases bowel frequency when it is high (diarrhoea) 12

Fibre is safe and generally well-tolerated in patients Total number of patient studies = 38 (1591 patients) Tolerance (GI symptoms including nausea, vomiting, flatulence, abdominal cramps, bloating) Reported (No. of studies) No difference between fibre and fibre-free free (No. of studies) Difference between fibre and fibre-free free (No. of studies) 21 17 flatulence (2) distension (1) vomiting (1) Feed intake 22 19 intake (2) intake (1) 13

Fibre is safe and generally well-tolerated in patients Total number of patient studies = 38 (1591 patients) Tolerance (GI symptoms including nausea, vomiting, flatulence, abdominal cramps, bloating) 6 patients on Reported No inulin; difference Difference between fibre and between fibre and 11 patients on fibre-free free fibre-free free (No. of studies) hydrolysed (No. of studies) guar (No. of studies) gum 21 17 flatulence (2) distension (1) vomiting (1) Feed intake 22 19 intake (2) intake (1) 14

Fibre is safe and generally well-tolerated in patients Total number of patient studies = 38 (1591 patients) Tolerance (GI symptoms including nausea, vomiting, flatulence, abdominal cramps, bloating) 6 patients on Reported No difference Difference 2 patients on inulin; between fibre and between Fybogel fibre and 11 patients on fibre-free free fibre-free free (No. of studies) hydrolysed (No. of studies) guar (No. of studies) gum 21 17 flatulence (2) distension (1) vomiting (1) Feed intake 22 19 intake (2) intake (1) 15

Fibre is safe and generally well-tolerated in patients Total number of patient studies = 38 (1591 patients) Tolerance (GI symptoms including nausea, vomiting, flatulence, abdominal cramps, bloating) 6 patients on Reported No difference Difference 2 patients on inulin; between fibre and between Fybogel fibre and 11 patients on fibre-free free fibre-free free (No. of studies) hydrolysed (No. of studies) guar (No. of studies) gum 21 17 flatulence (2) distension (1) 7 patients on vomiting (1) fibre Feed intake 22 19 intake (2) intake (1) 16

Fibre is safe and generally well-tolerated in patients Total number of patient studies = 38 (1591 patients) Tolerance (GI symptoms including nausea, vomiting, flatulence, abdominal cramps, bloating) 6 patients on Reported No difference Difference 2 patients on inulin; between fibre and between Fybogel fibre and 11 patients on fibre-free free fibre-free free (No. of studies) hydrolysed (No. of studies) guar (No. of studies) gum 21 17 flatulence (2) distension (1) 7 patients on vomiting (1) fibre Feed intake 22 19 intake (2) 9 patients on soy polysaccharide intake (1) 17

Reasons why all enteral formulas should contain fibre Recognised as essential part of normal diet Many physiological effects relevant for enterally fed patients Increasingly used in clinical practice Reduces diarrhoea Improves objective measures of bowel function Safe and well-tolerated 18

Conclusion Recognised as essential part of normal diet There is a clear rationale to support the inclusion of fibre Many physiological effects relevant for enterally fed patients Increasingly used in clinical practice (preferably from mixed sources) in all enteral feeds Reduces diarrhoea Improves objective measures of bowel function Safe and well-tolerated 19

ALL ENTERAL FEEDS SHOULD CONTAIN FIBRE *** AGAINST THE MOTION *** Tim Maximum Impaction Bowling or Tim Bowel Bowling or Tim Full of s**t Bowling

Why are we asking this question? For improvement in bowel function as perceived ed by the patient and/or carer No other reason Transit time, microflora, marginal changes in bowel frequency are of academic interest but little practical relevance to the individual patient

2 different patient populations Acute Critical care, post-op, neurological event, supplement intake during acute illness Catabolic (Often) younger Medication (antibiotics, analgesics) Low albumin Bed bound/immobile Dietary intake different from normal Chronic Clinically/metabolically (more) stable (Often) older Bed bound/immobile/lack of exercise in the long term Depressed ± antidepressants Rationalised (?) medication Rti Rationale for feeding } Aetiology for bowel disturbance Arguments for fibre } } Very different

Diarrhoea in the acute setting Study name Group by Ward Fibre type Odds ratio and 95% C non- Spapen et al 2001 Guar Guenter et al 1991 Soy Frankenfield & Beyer 1989. Soy Dobb & Towler 1990 Soy Schultz et al 2000 Fiber mixture* Schultz et al 2000. Pectin Schultz et al 2000.. Fiber mixture* + pectin Hart & Dobb 1988 Soy Khalil et al 1998 non- Surgical Soy + oat Reese et al 1996 non- Surgical Soy Reese et al 1996. non- Surgical Soy Homann et al 1994 non- Surgical Guar Kruif et al 1993 non- Surgical Soy Richardson et al 1987 non- Surgical Soy Belknap et al 1997 non- Medical Psyllium Hofman et al 2001 non- Pediatric. Fiber mixture** non- Overall 001 0.01 01 0.1 1 10 100 Favors fiber 16 RCT s: 13 NS, 2 favour fibre, 1 favours fibre-free: CI 0.48-0.96! alone NS Heterogeneity of patients Elia Favors et fiber-free al, in press Publication bias Heterogeneity of φ of diarrhoea (rates 9-92%) Maybe if you looked hard enough you could find a subgroup that would benefit, but overall not persuasive

Diarrhoea in the chronic setting Studies of diarrhoea in chronic illness setting = 0 ARGUMENT FOR FIBRE IN PREVENTING DIARRHOEA?*@!!*?$&?

Constipation Definition - hard stool? -difficulty defaecating Acute setting: - BO? - abdo pain etc etc 7 RCT s (2, 3 surgical, 2 medical: n=293) no differences Chronic setting: 1 study no difference 5 studies looking at laxative use. Only 1 study showed significant ARGUMENT FOR FIBRE IN PREVENTING CONSTIPATION?*@!!*?$&?

1. Stool frequency Other possibly relevant factors Acute: 3 studies = bowels 0.22/day Chronic: 6 studies = bowels 0.27/day Significant figures in meta-analysis, but how relevant for the patient? 2. Stool consistency Chronic care: 3 studies: 3= no difference : 6 studies: 2 = no difference 4 = more formed stool (?important in ) Surgery: 1 study: 1 = no difference Medicine 5 studies: 3 = no difference 2 = softer formed stool 3. Tolerance No differences overall. Some flatulence, abdo distension with fibre

1. Human volunteer studies 2. Transit time Only 3 studies: All = no difference 3. Faecal mass with fibre BIG DEAL! 4. Microflora/SCFA s Irrelevant factors Interesting, but understanding and interpretation of normality, clinical relevance etc g, g p y, is rudimentary

Conclusions Acute Chronic Diarrhoea Constipation?? slight benefit with fibre in some patients No difference No difference/evidence Stool frequency bowels 0.22/day bowels 0.27/day Consistency Tolerance Overall no difference. No difference? more formed stool in No difference

You might say Well, why not add fibre no harm done? You might, but this would not be practising evidence-based medicine R b th ti i ALL t l f d h ld Remember the motion is ALL enteral feeds should contain fibre

So. SHOULD ALL ENTERAL FEEDS CONTAIN FIBRE? NO

Great height

Great height